ClinicalTrials.gg
Status unknownNCT00668850Updated Jun 8, 2011

Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin

A Phase 3 interventional study of Generex Oral-lyn™ and Regular human insulin in Diabetes Mellitus, sponsored by Generex Biotechnology Corp.. Status unknown at 74 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-06-08.

Sponsored by Generex Biotechnology Corp. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2011), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing insulin in Diabetes Mellitus — 1 open to participants now, 2 under way, none of them phase 3. Insulin · Diabetes Mellitus.

Planned enrollment
10th of 49
500 · median 74
Started
2008
with 3 others
Phase 3
11 of 51
none open now
Registered
17th of 51
by date

Among the 51 studies testing insulin in Diabetes Mellitus, this one is the 10th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2008, is one of 11 in phase 3, and was the 17th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 51 studies testing insulin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing insulin in Diabetes Mellitus, or all of them as a file.
02

Study summary

To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy.

Read the detailed description

This is a 26 week open-label, randomized, multi-center, active comparator study to compare oral spray insulin (Generex Oral-lyn™) with regular human insulin therapy as measured by HbA1c, and number of hypoglycaemic episodes in type-1 diabetes mellitus subject. All subjects will be on BID NPH intermediate acting insulin therapy. If subject is using long acting insulin (Glargine, Detemir, etc.), he/she must be switched to NPH intermediate acting insulin. If on insulin analogue (Novolog, Lispro, Aspart, Aphidra, Glulisine, or any other analogue available in the subject's geographical area), the subject must be switched to regular human insulin 3 times a day.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be male or female between the ages 18 to 75 years
  • Type 1 diabetes mellitus patients (according to ADA and/or WHO classification) who have >1 year history of type 1 DM and are currently managed with daily insulin injections totalling 0.3 to 0.8 IU/kg of body weight;
  • Current physical examination, vital signs and at screening that reveals no abnormalities;
  • Have a (BMI) \<27;
  • 8.5% (inclusively)\<Have a glycosylated haemoglobulin
  • Willing and able to follow the American Diabetes Association diet guidelines for type 1 diabetes; be able to commit to perform home blood glucose monitoring and record values as well as hypoglycemic events
  • Willing to give written prior to admission into the study.

Exclusion criteria

Exclusion Criteria:

  • Have a significant active asthma or suspected abnormalities of buccal mucosa; cardiovascular, cerebrovascular, hepatic, renal, gastrointestinal, hematological, or auto-immune disease (other than auto-immune thyroid disease); history of athopy or drugs allergy
  • Have evidence of unstable retinopathy (defined as pre-proliferative or proliferative retinopathy currently requiring photocoagulation therapy), nephropathy or neuropathy (gastroparesis or orthostatic hypotension);
  • Have hypoglycemia unawareness;
  • Have had more than one episode of severe hypoglycemia with seizure or coma or ketoacidosis within the past 12 months;
  • Have a blood pressure in excess of 160/100 mmHg at the Screening visit;
  • Have had any acute illness within the 2 weeks prior to screening;
  • Have a history of drug or alcohol abuse that in the opinion of the Investigator would interfere with participation in the protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    1

    Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose

    Drug: Generex Oral-lyn™

  • Active comparator
    2

    Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.

    Drug: Regular human insulin

Interventions

  • Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose

    Also known as: buccal Insulin spray

  • Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.

    Also known as: insulin

06

What researchers measure

Primary outcomes

  1. To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy

    Time frame: change in HbA1c from the Day 0 (V3) to Day 180 (V9) of Treatment Phase.

Secondary outcomes

  1. To evaluate the safety, tolerability, and satisfaction with Generex Oral-lyn™ therapy when administered by the RapidMist™ Diabetes Management System

    Time frame: 26 week

07

Study locations

74 sites
  • Coastal Biomedical Research Inc. at Santa Monica
    2001 Santa Monica Blvd Suite 390W, California 90404, United States
  • The Center for Diabetes & Endocrine Care at Hollywood
    1150 N. 35th Ave Suite 590, Florida 33021, United States
  • Physicians Research Group at Indianapolis
    7400 North Shadeland Ave, Indiana, United States
  • MODEL Clinical Research at Baltimore
    6535 North Charles Street Suite 400N, Maryland 21204, United States
  • Grunberger Diabetes Institute at Bloomfield Hills
    43494 Woodward Ave Suite 208, Michigan 48302, United States
  • Beth Israel Medical Center, Geral J. Friedman Diabetes Institute at New York
    317 East 17th Street Room 7F05 8th Floor, New York 10003, United States
  • Multiple Health Research, LLC. at Arlington
    501 Rita Lane Suite 113, Texas 76014, United States
  • University of Texas Southwestern Medical Center at Dallas
    5323 Harry Hines Blvd, Texas 75390-8858, United States
  • University Multiprofile Hospital for Active Treatment "Aleksandrovska"
    1 St. Georgi Sofiysky St, Sofia 1431, Bulgaria
  • University Multiprofile Hospital for Active Treatment at Varna
    1 Hristo Smirnensky St, 9010, Bulgaria
  • Multiprofile Hospital for Active Treatment at Stara Zagora
    11 Armeyska St., 6003, Bulgaria
  • University Multiprofile Hospital for Active Treatment at Plovdiv
    15A Vassil Aprilov Blvd, 4002, Bulgaria
  • Multiprofile Hospital for Active Treatment at Ruse
    2 Nezavisimost St, 7002, Bulgaria
  • University Multiprofile Hospital for Active Treatment at Pleven
    8A Georgi Kotchev St, 5800, Bulgaria
  • The Bailey Clinic at Red Deer
    #108 3947 50A Avenue, Alberta T4N 6V7, Canada
  • Calgary Metabolic Education & Research Centre at Calgary
    #23, 4411-16th Avenue NW, Alberta T3B 0M3, Canada
  • West Edmonton Diabetes Centre
    10230 142 St Nw # 25, Edmonton, Alberta T5N 3Y6, Canada
  • Instituto de Endocrinologia IEMYR
    Avenida La Coruña Nº 6337 y San Ignacio, Quito, Ecuador
  • Bydgoszcz Diabetology and Endocrinology Center at Bydgoszcz
    ul. Baczynskiego 17, 85 - 822, Poland
  • OSTEOMED Medical Center at Warszawa
    ul. Bialobrzeska 40A, 02 - 341, Poland
  • Chair and Department of Internal Medicine and Diabetology, Voivodship Brodnowski Hospital at Warszawa
    ul. Kondratowicza 8, 03 - 242, Poland
  • Diabetology Clinic for Adults, NZOZ Elblag Diabetology Center
    ul. Krolewiecka 146, 82 -300, Poland
  • TeMeD - Clinical Trials at Rzeszow
    ul. Mazowiecka 56, 35-324, Poland
  • Provincial Centre of Diabetology and Metabolic Diseases, M.Pirogow Provincial Specialist Hospital at Lodz
    ul. Nowa 30/32, 90-030, Poland
  • Silesia Osteoporosis Center at Katowice
    ul. Opolska 11/3, 40-084, Poland
  • TeMeD - Clinical Trials at Nowy Targ
    ul. Wojska Polskiego 14, 34-400, Poland
  • NZOZ Specialist Centre of Internal Medicine and Diabetology Malgorzata Arciszewska at Bialystok
    ul. Zamenhofa 10/20, 15 - 435, Poland
  • Celis Aguilera 10B
    Fajardo, 00738, Puerto Rico
  • Puerto Medical Center
    San Juan, 364246, Puerto Rico
  • Clinical Research, Puerto Rico
    San Juan, Puerto Rico
  • "Nicolae Malaxa" Clinical Hospital, Department of Diabetes, Nutrition and Metabolic Diseases at Bucharest
    12 Vergului St Sector 2, 022441, Romania
  • Timisoara Emergency Clinical County Hospital, Clinic of Diabetes, Nutrition and Metabolic Diseases at Timisoara
    156 Iosif Bulbuca Av, 300736, Romania
  • Satu Mare County Hospital, Department of Diabetology and Nutrition Diseases at Satu Mare
    2-3 Eroii Revolutiei Square, 440055, Romania
  • Private Practice at Galati
    25 Constructorilor St, Bl. E5/64, 800371, Romania
  • Cluj Emergency Clinical County Hospital, Department of Diabetes, Nutrition and Metabolic Diseases at Cluj-Napoca
    3-5 Clinicilor St, 400006, Romania
  • Oradea Clinical County Hospital, Department of Diabetes, Nutrition and Metabolic Diseases at Oradea
    33 Republicii St, 410032, Romania
  • National Institute of Diabetes, Nutrition and Metabolic Diseases, 1st Clinical Department of Diabetes, Nutrition and Metabolic Diseases at Bucharest
    5-7 Ion Movila St Sector 2, 020475, Romania
  • Cardiology Private Practice at Bala Mare
    6/72 Independentei St, 430123, Romania
  • Private Practice Nicodiab SRL at Bucharest
    92 Polona St, Bl 17 A+B, Sc. 1, Ap. 2, 010507, Romania
  • Municipal Medical Institution: City Hospital # 2, Municipal Diabetology and Rehabilitation Center
    1 3rd -Transportnaya str., Omsk, 644021, Russian Federation
  • St. Petersburg State Medical Institution: St. George Municipal Hospital
    1 Severny Pr., St.Petersburg, 194354, Russian Federation
  • Municipal Medical Institution: Medical Unit "Izhmash", Municipal Endocrinology Center
    1 Truda str., Izhevsk, 426067, Russian Federation
  • St. Petersburg State Medical Institution: Municipal Consulting and Diagnostic Center #1, St. Petersburg Territorial Diabetology Center
    10 Siqueirosa str., St. Petersburg, 194354, Russian Federation
  • Federal State Institution: Endocrinology Research Center under the Federal Agency for High-Tech Medical Care, Department of Therapeutic and Surgical Methods for Treatment of Diabetic Foot
    11 Dmitriya Ulyanova str., Moscow, 117036, Russian Federation
  • Federal State Institution: Endocrinology Research Center under the Federal Agency for High-Tech Medical Care, Department of Training and Psychosocial Rehabilitation of Patients with Diabetes Mellitus
    11 Dmitriya Ulyanova str., Moscow, 117036, Russian Federation
  • St. Petersburg State Medical Institution: Municipal Hospital of St. Elizabeth
    14 Vavilovykh str., St. Petersburg, 195257, Russian Federation
  • State Medical Institution: Nizhny Novgorod Regional Clinical Hospital n.a. N.A. Semashko
    190 Rodionova str., Nizhny Novgorod, 603126, Russian Federation
  • Medical Institution Municipal Clinical Hospital #67
    2 "b" Salyama Adilya str., Moscow, 123423, Russian Federation
  • State Medical Institution: Kemerovo Regional Clinical Hospital
    22 Oktyabrsky Pr., Kemerovo, 650066, Russian Federation
  • State Medical Institution: Arkhangelsk Regional Clinical Hospital
    292 Lomonosova pr., Arkhangelsk, 163045, Russian Federation
  • State Medical Institution: Republican Hospital
    3 Pirogova str., Petrozavodsk, ,, 185019, Russian Federation
  • St. Petersburg State Medical Institution:Municipal Outpatient Clinic #51
    33/35 Kosmonavtov Pr., St. Petersburg, 196211, Russian Federation
  • Moscow State Medical Institution Municipal Clinical Hospital #68
    4 Shkuleva str., Moscow, 109263, Russian Federation
  • St. Petersburg State Medical Institution: City Aleksandrovskaya Hospital
    4 Solidarnosti Pr., St. Petersburg, 193312, Russian Federation
  • Federal State Medical Institution: All-Russia Center for Urgent Care and Radiation Medicine n.a. A.M. Nikiforov under the Russian Emergency Control Ministry
    4/2 Lebedeva str., St.Petersburg, 194044, Russian Federation
  • St. Petersburg State Medical Institution: Municipal Multifield Hospital #2
    5 Uchebny Per., St. Petersburg, 194354, Russian Federation
  • State Higher Educational Institution: Tyumen State Medical Academy under the Federal Agency for Healthcare and Social Development, Multifield Clinic
    54 Odesskaya str., Tyumen, 625023, Russian Federation
  • "Diabetes" Center Company Limited
    56 Sovetskoi Armii str., Samara, 443067, Russian Federation
  • State Medical Institution: Consulting and Diagnostic Center of Komi Republic, Diabetology Center
    6 Kuratova str., 167981, Syktyvkar, Russian Federation
  • State Medical Institution: Murmansk Regional Consulting and Diagnostic Center
    6 Pavlova str., Building 4, Murmansk, 183047, Russian Federation
  • Municipal Medical Institution: Municipal Clinical Hospital #1, Municipal Diabetology Center
    6 Zalesskogo str., Novosibirsk, 630047, Russian Federation
  • State Higher Educational Institution: St. Petersburg State Medical University n.a. I.P. Pavlov under the Federal Agency for Healthcare and Social Development
    6/8 L. Tolstogo str., St. Petersburg, 197022, Russian Federation
  • State Institution: Moscow Regional Research Clinical Institute n.a. M.F.Vladimirsky
    61/2 Shchepkina str., Moscow, 129110, Russian Federation
  • State Higher Educational Institution: Ural State Medical Academy under the Federal Agency for Healthcare and Social Development; Family Medicine Clinic
    7 Kluchevskaya str., Ekaterinburg, 620219, Russian Federation
  • State Medical Healthcare Institution: Chelyabinsk Regional Clinical Hospital
    70 Vorovskogo str., Medgorodok, Chelyabinsk, 454076, Russian Federation
  • State Medical Institution:Territorial Endocrinology Center, Territorial Diabetology Center
    9 Artema str., Stavropol, 355045, Russian Federation
  • Regional Endocrinology Center, Diabetology Department at Lviv
    1, Ostrozskoho St., Lviv, 79010, Ukraine
  • Ukrainian Research and Development Center for Endocrine Surgery and Endocrine Organ and Tissue Transplantation under the Ministry of Health of Ukraine, General Endocrine Pathology Department at Kiev
    121, Kharkovskoe Shosse, Kiev, 02175, Ukraine
  • M.V. Sklifosovskyi Regional Clinical Hospital, Endocrinology Department at Poltava
    23, Shevchenko St., 36024, Ukraine
  • City Clinical Hospital #9, Endocrinology Department at Dnipropetrovsk
    29, Vorontsova St., 49023, Ukraine
  • M.O. Semashko Republican Clinical Hospital, Endocrinology Department at Simferopol
    69 Kievskaya St., 95017, Ukraine
  • V.P. Komisarenko Institute for Endocrinology and Metabolism under the Ukrainian Academy of Medical Sciences, Clinical Diabetology Department at Kiev
    69, Vyshgorodskaya St., Kiev, 04114, Ukraine
  • V.P. Komisarenko Institute for Endocrinology and Metabolism under the Ukrainian Academy of Medical Sciences, General Endocrine Pathology Department at Kiev
    69, Vyshgorodskaya St., Kiev, 04114, Ukraine
  • V.Ya. Danylevskyi Institute for Endocrine Pathology under the Ukrainian Academy of Medical Sciences, Clinical Endocrinology Department at Kharkov
    Pomerky 27, Kharkov, 61070, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Aug 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2008
First posted
Apr 29, 2008
Start
Apr 2008
Primary completionEst.
Aug 2011
CompletionEst.
Sep 2011
Last update
Jun 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00668850
Lead sponsor
Generex Biotechnology Corp.
Collaborators
OSMOS Clinical Research, Inc, PSI Pharma Support Intl, Nextrials, Inc., eResearch Technology, Inc., Hoffmann-La Roche, ACM Pivotal Global Central Laboratory
First posted
Apr 29, 2008
Start date
Apr 2008
Primary completion
Aug 2011 (estimated)
Completion
Sep 2011 (estimated)
Last update
Jun 8, 2011

Study contacts

Gerald Bernstein,, MD
study chair · Generex Biotechnology Corp.
Jaime Davidson, MD
study director · Generex Biotechnology Corp.
Philip Raskin, MD
principal investigator · University of Texas, Southwestern Medical Center at Dallas

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion